Navigation Links
Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
Date:6/10/2011

NEW YORK, June 10, 2011 /PRNewswire/ -- Newswise -- Osteoarthritis (OA) is one of the most pressing health care challenges of our time, affecting 27 million Americans. In an effort to elucidate the latest information in diagnosis, treatment, research and prevention, Hospital for Special Surgery (HSS) will host an international Osteoarthritis Summit on June 17 and June 18.

The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together a multidisciplinary group of thought leaders from the United States, Canada, Europe and Australia. Renowned physicians, scientists and industry leaders will describe current research, the most promising avenues for future investigation, the latest diagnostic tools and treatments, public health strategies and the most recent information on preventing OA.

"Public health data indicate that the prevalence, impact and economic consequences of osteoarthritis are expected to rise dramatically within the next several decades. Clearly, understanding and preventing this disease is an urgent research challenge," said Steven Goldring, M.D., chief scientific officer at Hospital for Special Surgery and co-director of the conference.

"By bringing together a group of leading international experts, we will develop a consensus document on future directions for OA research, prevention and treatment," said Timothy Wright, Ph.D., Kirby chair of orthopedic biomechanics at HSS and co-director of the event.

Orthopedic surgeons, rheumatologists, scientists and biomechanical engineers -- experts in the major research and clinical aspects of the disease--as well as leaders from the pharmaceutical, device and insurance industries will be among 35 speakers discussing a wide range of topics. The two-day-long event will take place at the Richard Menschel Conference Center at HSS on Friday, June 17, starting at 9 a.m., and on Saturday, June 18, starting at 8 a.m.

Amon
'/>"/>

SOURCE Hospital for Special Surgery
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
2. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
3. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
4. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
5. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
6. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
7. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
8. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
9. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
10. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
11. Childrens Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Pharma AG, today,announced a substantial expansion of its ... Medical Officer and Head of Global Clinical,Development, Dr. ... Dr,Hans Rensland as Vice President Regulatory Affairs, Dr. ... Dr. Markus Vogt as Vice,President of Quality and ...
... A combination of two drugs can selectively block pain-sensing ... such as touch, according to a new study by ... suggests an improved way to treat pain from childbirth ... new treatments to help the millions of Americans who ...
... Troy J. Campione, Ph.D., Joins Solazyme Executive Team, ... Solazyme, a,bioscience company pioneering biofuels and health/wellness products ... the position of senior,vice president of business development. ... finalization of,partnership agreements and contracts with major companies. ...
Cached Biology Technology:Nitec Pharma Expands Senior Management Team 2Nitec Pharma Expands Senior Management Team 3Nitec Pharma Expands Senior Management Team 4Treatment blocks pain without disrupting other functions 2Treatment blocks pain without disrupting other functions 3Solazyme Announces New Senior Vice President of Business Development 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... GBIF Campaign? , Different users of the GBIF network ... of various types. Given the small size and coordination ... central activities to meet all of these needs. However, ... the GBIF network do coincide with the needs of these ...
... wont be making a stop at the Smithsonians National ... with love and romance, mating and dating at the ... encounter. Successful breeding is often much more complicated ... nature to take its course. Animals in captivity need ...
... coursing through the veins of men living in the North ... has been just published. Focusing on the Wirral in ... surnames were in existence as far back as medieval times, ... specifically linked to Scandinavian ancestry. The collaborative study, by ...
Cached Biology News:4 GBIF-endorsed campaigns underway 24 GBIF-endorsed campaigns underway 34 GBIF-endorsed campaigns underway 44 GBIF-endorsed campaigns underway 5Science, not romance, controls mating at Smithsonian's National Zoo 2Science, not romance, controls mating at Smithsonian's National Zoo 3Unravelling the Northwest's Viking past 2
... epitope recognized by A300-183A maps ... 5 of human quaking homolog ... 9444). The epitope is ... 2, 3, 4, 6, 7 ...
... ml Dynabeads Epoxy (4.5 m). Hydrophobic ... groups. Ideal for coupling of antibodies for ... initial coupling with covalent binding of primary ... groups (SH)) occurring within 16-20 hours. Coupling ...
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
St. Louis encephalitis Immunogen: St. Louis encephalitis. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: